NDAINTRAVENOUSEMULSION
Approved
Aug 2008
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
6/8 — Strong
CLEVIPREX (clevidipine) by Chiesi is calcium channel antagonists [moa]. Approved for dihydropyridine calcium channel blocker [epc]. First approved in 2008.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLEVIPREX (clevidipine) is an intravenous dihydropyridine calcium channel blocker approved in 2008 for acute hypertension management. It works by antagonizing L-type calcium channels to produce rapid, titratable blood pressure reduction in acute care settings. The drug is formulated as an oil-in-water emulsion for IV infusion in perioperative and critical care environments.
Peak5.3 years to LOE
Product is at peak commercial maturity with established market presence; brand team likely stable in size with focus on retention and specialty care penetration.
Mechanism of Action
Calcium Channel Antagonists
Pharmacologic Class:
Dihydropyridine Calcium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
Started Jun 2024
1,000 enrolled
Intracerebral HemorrhageStrokeHypertension
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
Started Jul 2023
378 enrolled
Hypertensive Emergency
Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)
Started Mar 2014
22 enrolled
Pediatric Perioperative Blood Pressure Management
Career Relevance
CLEVIPREX roles are concentrated in specialty/hospital commercial teams focused on perioperative and critical care stakeholder engagement. Career opportunities emphasize account management, clinician education, and formulary penetration in acute care settings rather than primary care expansion.
Worked on CLEVIPREX at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.